A Phase I Dose Escalation Trial to Investigate the Safety, Tolerability, and Explorative Efficacy, Following Environmental Allergen Exposure in a Chamber, of DM-101PX in Participants With Birch Pollen Allergy
Latest Information Update: 07 Apr 2025
At a glance
- Drugs DM 101 (Primary)
- Indications Tree pollen hypersensitivity
- Focus Adverse reactions
- Sponsors Desentum
Most Recent Events
- 02 Apr 2025 Positive results presented in the Desentum Media Release.
- 22 Mar 2024 Status changed from active, no longer recruiting to completed.
- 18 Dec 2023 Status changed from recruiting to active, no longer recruiting.